Tenofovir alafenamide/ emtricitabine · Descovy
Small molecule
Evidence outlook
Approved: HIV
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (5)
- HIV-1 PrEP ( 1.2 ): DESCOVY is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex.
- Descovy in combination with other antiretroviral agents for HIV-1 in adults and adolescents aged 12 and older weighing at least 35 kg
- Descovy Combination Tablets LT/HT (emtricitabine + tenofovir alafenamide fumarate), anti-HIV; approved to Japan Tobacco, marketed by Torii Pharmaceutical; marketing approval transferred to Gilead Sciences K.K. on 2019-12-01
- Treatment of HIV-1 Infection DESCOVY is indicated in combination with other antiretrovirals (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg. HIV-1 Pre-Exposure Prophylaxis (PrEP) DESCOVY is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing ≥ 35 kg, excluding individuals at risk from receptive vaginal sex. For more information on the DESCOVY HIV-1 PrEP...
- Descovy: with other antiretrovirals for HIV-1 infected adults and adolescents 12 years and older, 35 kg or more
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02121795 NCT02121795 · HIV This was a randomized, quadruple-blind, active-controlled trial of 668 participants, with 333 receiving F/TAF and 330 receiving FTC/TDF in the treated analysis. The primary clinical endpoint was met: virologic suppression was 94.3% versus 93.0%, and the prespecified non-inferiority confidence interval remained within the 10% margin. Registry: NCT02121795 | 3 | Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis 2015-08-12 | Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis (Week 48): F/TAF + 3rd Agent 94.3 percentage of participants | FTC/TDF + 3rd Agent 93 percentage of participants | Reliable signal | link ↗ |
View 8 more trials
NCT02469246 NCT02469246 · HIV This was a randomized, double-blind, active-controlled trial of 567 adults, with F/TAF compared directly against ABC/3TC. The primary clinical endpoint, HIV-1 RNA below 50 copies/mL at Week 48, met the prespecified non-inferiority margin, supporting strong evidence that switching to F/TAF maintained virologic suppression in this study. Winston et al. (Lancet HIV, 2018; PMID 29475804) report different figures for this outcome, 90% (227 of 253) with F/TAF and 93% (230 of 248) with abacavir plus lamivudine, because the paper analysed the 501 participants enrolled by the week 48 primary-analysis cutoff. Registry: NCT02469246 | 3 | Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm 2017-12-11 | Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm (Week 48): F/TAF 88.6 percentage of participants | ABC/3TC 92.4 percentage of participants | Reliable signal | link ↗ |
NCT01797445 NCT01797445 · HIV This was a randomized, double-blind, active-controlled trial with 872 participants and an objective, clinically relevant primary endpoint of HIV-1 RNA below 50 copies/mL. The primary result met the prespecified noninferiority criterion, but no primary-endpoint power calculation is reported in the provided record, so the evidence is graded moderate rather than strong. Registry: NCT01797445 | 3 | Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48 2014-09-19 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT01815736 NCT01815736 · HIV This was a large randomized, controlled trial, and switching to the tenofovir alafenamide regimen met its non-inferiority goal for keeping HIV-1 RNA below 50 copies/mL (difference 2.7%, 95% CI -0.3 to 5.6, against a 12% margin). Participants and doctors knew which treatment was given, but the endpoint is a laboratory measure of viral load that this knowledge cannot change. Registry: NCT01815736 | 3 | Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 2015-03-16 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT01818596 NCT01818596 · HIV This was a single-group, open-label study with 252 enrolled participants and no placebo or active comparator. Its primary endpoints assessed renal safety through changes in eGFR, and although results were reported, there was no between-group primary endpoint comparison to test. Registry: NCT01818596 | 3 | Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24 (Baseline; Week 24); Change From Baseline in eGFR Calculated by the Chronic Kidney Disease Epidemiology Collaboration Method Based on Cystatin C (eGFR_CKD-EPI,cysC) at Week 24 (Baseline; Week 24); Change From Baseline in eGFR Calculated by the CKD-EPI Method Based on Serum Creatinine (eGFR_CKD-EPI,Creatinine) at Week 24 (Baseline; Week 24) 2014-07-31 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT02600819 NCT02600819 · HIV The study was open-label, non-randomized, and had no comparator arm, so its findings cannot establish how E/C/F/TAF compares with another treatment. Its primary endpoint was safety rather than comparative efficacy, and 32.7% of 55 participants experienced a grade 3 or higher treatment-emergent adverse event through week 48. Registry: NCT02600819 | 3 | GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48 (First Dose Date Up to Week 48) 2017-09-29 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT01854775 NCT01854775 · HIV The study was open-label, nonrandomized, and single-arm, with all 129 participants receiving E/C/F/TAF and no placebo or active comparator. Its primary outcomes were pharmacokinetic measurements and adverse events rather than a controlled clinical efficacy comparison, so the reported results cannot establish the drug’s benefit relative to another treatment. Registry: NCT01854775 | 2/3 | Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1) (0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4); PK Parameter: AUCtau of EVG (Cohort 2) (0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4); PK Parameter: AUCtau of EVG (Cohort 3) (0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2); PK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1) (0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4); PK Parameter: AUClast of TAF (Cohort 2) (0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4); PK Parameter: AUCtau of TAF (Cohort 3) (0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2); Cohort 1: Percentage of Participants With All Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs) (From first dose date up to Week 24); Cohort 2: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs (From first dose date up to Week 24); Cohort 3: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs (From first dose date up to Week 24) 2020-05-11 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT02016924 NCT02016924 · HIV Registry: NCT02016924 | 2/3 | Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, TAF, and TFV (Predose on Day 1, and postdose up to Week 48); Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) Through Week 24 (First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)); Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities Through Week 24 (First dose date up to Week 24 plus 30 days (Cumulative data through Week 24)) 2025-06-13 | Results not posted; external-source review pending | not yet graded | link ↗ |
DISCOVER NCT02842086 · HIV This was a large randomized, double-blind trial against an effective active comparator (F/TDF), with new HIV infection as the primary endpoint. F/TAF met its prespecified non-inferiority test (rate ratio 0.47, upper confidence limit 1.15, below the 1.62 margin). A power calculation was reported (2,500 participants per arm) and each arm enrolled more than that. Registry: NCT02842086 | 3 | Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)) 2019-01-31 | Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (34)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (7)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Studied as part of a combination product (4)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Competitive landscape
Other HIV reverse transcriptase drugs
Cabotegravir/rilpivirine (Cabenuva), Doravirine, Doravirine/islatravir (Idvynso), Emtricitabine (Emtriva), Emtricitabine/tenofovir disoproxil fumarate and 8 more. Compare all 14 HIV reverse transcriptase drugs
This mechanism is crowded: 13 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for HIV: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tenofovir Alafenamide / Emtricitabine (Descovy): this drug | Approved | Small molecule | HIV reverse transcriptase | Reliable signal | NCT02842086: Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) | |
| Amprenavir | ApprovedUS marketing discontinued | Small molecule | HIV protease | not yet graded | No reviewed efficacy summary in this indication | |
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | Reliable signal | NCT03110380: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis). NCT02607956: Week 48 HIV-1 RNA <50 copies/mL: 89.4% B/F/TAF vs 92.9% DTG + F/TAF; difference -3.5 percentage points (95.002% CI -7.9 to 1.0); prespecified non-inferiority margin 12%. | |
| Bictegravir / Lenacapavir (Bixlenvo) | Approved | Small molecule | HIV integrase, HIV capsid | Partial signal | NCT05502341: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). | |
| Cabotegravir (Apretude) | Approved | Small molecule | HIV integrase | Reliable signal | NCT02720094: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281 | |
| Cabotegravir / Rilpivirine (Cabenuva) | Approved | Small molecule | HIV integrase, HIV reverse transcriptase | Weak signal | NCT03299049: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). NCT02938520: Virologic failure (HIV-1 RNA >=50 copies/mL, FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 4 weeks vs abacavir/dolutegravir/lamivudine: 2.1% vs 2.5%, adjusted difference -0.4% (95% CI -2.8 to 2.1); non-inferior against the 6% margin (CT.gov posted results). | |
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | Partial signal | NCT00110877: HIV RNA <400 copies/mL at Week 48 (per-protocol population): darunavir-ritonavir 77% (220/286) vs lopinavir-ritonavir 68% (199/293); estimated difference 9% (95% CI 2-16). | |
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | Reliable signal | NCT01263015: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). NCT01449929: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 (Week 48): DTG 50 mg QD 90% vs DRV 800 mg + RTV 100 mg QD 83% | |
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | Reliable signal | NCT02403674: Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). NCT02275780: Week 48 HIV-1 RNA <50 copies/mL: 83.8% doravirine vs 79.9% darunavir/ritonavir; treatment difference 3.913 percentage points (95% CI -1.590 to 9.415), non-inferiority margin -10 percentage points. | |
| Doravirine / Islatravir (Idvynso) | Approved | Small molecule | HIV reverse transcriptase, HIV-1 Reverse Transcriptase | Partial signal | NCT05630755: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). NCT04233879: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3% | |
| Elvitegravir (Stribild) | Approved | Small molecule | HIV integrase | Partial signal | NCT01095796: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% | |
| Emtricitabine (Emtriva) | Approved | Small molecule | HIV reverse transcriptase | Partial signal | NCT00112047: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants | |
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | Partial signal | NCT00323544: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. | |
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | Reliable signal | NCT00254046: Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 NCT00255099: Confirmed viral load <50 copies/mL at Week 24 (intention to treat): etravirine (TMC125) 62% (183/295) vs placebo 44% (129/296); difference 18% (95% CI 11-26; p=0.0003). | |
| Fostemsavir (Rukobia) | Approved | Small molecule | HIV gp120 | Partial signal | NCT02362503: Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Randomized Cohort-fostemsavir 600 mg BID -0.791 Log10 copies per milliliter (c/mL) (95% CI -0.885 to -0.698) vs Randomized Cohort-Placebo -0.166 Log10 copies per milliliter (c/mL) (95% CI -0.326 to -0.007) NCT01384734: HIV-1 RNA < 50 copies/mL at Week 24: fostemsavir 400 mg BID 80% (95% CI 66.3 to 90), 800 mg BID 69% (54.6 to 81.7), 600 mg QD 76% (62.5 to 87.2) and 1200 mg QD 72% (57.5 to 83.8) vs the atazanavir/ritonavir reference arm 75% (60.4 to 85.7). | |
| Ibalizumab (Trogarzo) | Approved | Monoclonal antibody | CD4 receptor | Weak signal | NCT02475629: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14): Open-Label Ibalizumab Plus OBR 82.5% (95% CI 67.72% to 92.66%) | |
| Lenacapavir (Sunlenca) | Approved | Small molecule | HIV capsid | Partial signal | NCT04150068: Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants NCT04143594: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm (Week 54): Group 1: SC LEN+(F/TAF→ TAF) 90.4% vs Group 2: SC LEN + (F/TAF → BIC) 84.9% vs Group 3: Oral LEN + F/TAF 84.6% vs Group 4: B/F/TAF 92.0%; p=0.7178 (Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF), p=0.3900 (Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF), p=0.3797 (Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF) missed | |
| Lenacapavir (Yeztugo) | Approved | Small molecule | HIV capsid | Reliable signal | NCT04925752: HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025). NCT04994509: HIV incidence: 0 infections in 2,134 on twice-yearly lenacapavir (0 per 100 PY; 95% CI 0.00-0.19) vs background incidence 2.41 per 100 PY (IRR 0.00; 95% CI 0.00-0.04; P<0.001) and vs F/TDF 1.69 per 100 PY (IRR 0.00; 95% CI 0.00-0.10; P<0.001) (PURPOSE 1, NEJM 2024). | |
| Maraviroc (Selzentry / Celsentri) | Approved | Small molecule | CCR5 co-receptor | Partial signal | NCT00098293: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population (Week 48): Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) — Less than 400 copies/mL: 61.5%; Less than 50 copies/mL: 55.8% | Maraviroc Twice Daily + CBV (DB) — Less than 400 copies/mL: 70.6%; Less than 50 copies/mL: 65.3% vs Efavirenz Once Daily + CBV (DB) — Less than 400 copies/mL: 73.1%; Less than 50 copies/mL: 69.3% | |
| Raltegravir (Isentress) | Approved | Small molecule | HIV integrase | Reliable signal | NCT00293254: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3) NCT00293267: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.7% (95% CI 71.8 to 82.9) vs Placebo + OBT 41% (95% CI 32 to 50.5) | |
| Rilpivirine (Edurant) | Approved | Small molecule | HIV reverse transcriptase | Reliable signal | NCT00540449: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%. NCT00543725: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 (Week 48): TMC278 — Responder: 291/340; Virologic failure: 24/340; Death: 1/340; Discontinued due to AE: 8/340; Discontinued due to other reason than AE: 16/340 vs Efavirenz — Responder: 276/338; Virologic failure: 18/338; Death: 3/338; Discontinued due to AE: 21/338; Discontinued due to other reason than AE: 20/338 | |
| Somatropin (Serostim) | Approved | Protein / enzyme therapeutic | Growth hormone receptor | Partial signal | NCT00082628: Change in visceral adipose tissue area at Week 12: -32.6 cm² Serostim (n=210) vs 0.5 cm² placebo (n=74), p<0.001. phase 3 result · pivotal pending NCT01077960: Primary endpoint: mean change in trunk fat from baseline to week 12, -1.7 kg (SD 1.4; n=106; p<0.001). phase 3 result · pivotal pending | |
| Tenofovir Disoproxil Fumarate (Viread) | Approved | Small molecule | HIV reverse transcriptase (RT) | Partial signal | NCT00528957: Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 (48 weeks): Tenofovir DF 83.3 percentage of participants | Stavudine or Zidovudine 91.8 percentage of participants | All TDF 85.4 percentage of participants missed NCT00352053: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA (Baseline to 24 Weeks): Tenofovir DF -1.58 log10 copies/mL (IQR -2.15 to -0.27) | Placebo -1.549 log10 copies/mL (IQR -2.36 to -0.34) missed | |
| Tesamorelin (Egrifta WR) | Approved | Peptide | Growth hormone-releasing hormone (GHRH) receptor | Partial signal | NCT00608023: Changes From Baseline in Fasting Blood Glucose at Week 52 (Baseline and Week 52): Tesamorelin 52 Weeks 0 mg/dL (Standard Deviation 16) missed | |
| Tipranavir (Aptivus) | Approved | Small molecule | HIV protease | Partial signal | NCT00144170: Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15% NCT00054717: Treatment Response at Week 48 (At week 48): Tipranavir(TPV)/Low Dose Ritonavir(r) 33.8% vs Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r) 16.2% | |
| ACC017 | Phase 3 | Small molecule | HIV integrase | Partial signal | NCT06719310: The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. | |
| Albuvirtide (Aikening) | Phase 3 | Peptide | HIV gp41 | Partial signal | NCT02369965: Primary, HIV-1 RNA <50 copies/mL at week 48 (mITT, interim analysis with 46 albuvirtide and 50 control patients at week 48): 80.4% (37/46) albuvirtide + lopinavir/ritonavir vs 66.0% (33/50) NRTIs + lopinavir/ritonavir; difference 14.4% (95% CI -3.0% to 31.9%) against a prespecified non-inferiority margin of -12%, met. | |
| Alimatravir | Phase 3 | Small molecule | HIV-1 Reverse Transcriptase | Weak signal | NCT06045507: Primary outcomes, safety (no formal efficacy test): participants with at least one adverse event 62/101 (3 mg), 69/101 (6 mg) and 66/99 (12 mg) monthly MK-8527 vs 31 on placebo; discontinuation due to an adverse event 0, 2 and 1 vs 2 (CT.gov posted results). | |
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | Partial signal | NCT04109183: 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05) | |
| Dapivirine (Dapivirine Vaginal Ring) | Phase 3 | Small molecule | HIV reverse transcriptase | Reliable signal | NCT01617096: HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). | |
| Islatravir | Phase 3 | Small molecule | HIV-1 Reverse Transcriptase | not yet graded | No reviewed efficacy summary in this indication | |
| Islatravir / Lenacapavir | Phase 3 | Small molecule | HIV-1 Reverse Transcriptase, HIV capsid | not yet graded | No reviewed efficacy summary in this indication | |
| Semzuvolimab | Phase 3 | Monoclonal antibody | CD4 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Teropavimab | Phase 3 | Monoclonal antibody | HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| Zinlirvimab | Phase 3 | Monoclonal antibody | HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| Elsulfavirine (Elpida) | Phase 2/3 | Small molecule | HIV reverse transcriptase | Partial signal | No reviewed efficacy summary in this indication | |
| Leronlimab | Phase 2/3 | Monoclonal antibody | CCR5 co-receptor | Weak signal | NCT02483078: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): PRO 140 — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 64%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 36% | Placebo — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 23%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 77% NCT02859961: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure (From T1 (first treatment administration) to week 48 (T48).): Part 1 - 350 mg Weekly Injections of PRO 140, Group A 23% | Part 1 - 525 mg Weekly Injections of PRO 140, Group B 43% | Part 1 - 700 mg Weekly Injections of PRO 140, Group C 45% | |
| Ulonivirine | Phase 2/3 | Small molecule | HIV reverse transcriptase | Weak signal | Featured results are safety only in this race | |
| 10-1074 | Phase 2 | Monoclonal antibody | HIV envelope | Weak signal | Featured results are safety only in this race | |
| 3BNC117 | Phase 2 | Monoclonal antibody | HIV envelope | Partial signal | NCT03041012: Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed. | |
| CL-197 | Phase 2 | Small molecule | HIV reverse transcriptase | Weak signal | No reviewed efficacy summary in this indication | |
| Dezecapavir | Phase 2 | Small molecule | HIV capsid | Partial signal | NCT06039579: Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969) | |
| Envafolimab | Phase 2 | Monoclonal antibody | PD-L1 | Weak signal | No reviewed efficacy summary in this indication | |
| HTI Vaccine (ChAdOx1.HTI / MVA.HTI) | Phase 2 | Vaccine | HIV-1 conserved epitopes (HTI) | Partial signal | NCT03204617: Primary, safety (grade 3 or 4 local and systemic reactions; no formal efficacy test): adverse events were mostly mild and transient, with no related serious adverse events. Secondary: HTI vaccines induced strong, broad CD4 and CD8 T-cell responses; all participants had detectable viral rebound during treatment interruption. | |
| Lipovirtide | Phase 2 | Peptide | HIV gp41 | Partial signal | No reviewed efficacy summary in this indication | |
| Lotivibart | Phase 2 | Monoclonal antibody | HIV envelope | Weak signal | NCT04871113: Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69) | |
| TMB-365 / TMB-380 | Phase 2 | Combination | CD4; HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| Trosunilimab | Phase 2 | Monoclonal antibody | α4β7 integrin | Partial signal | Featured results are safety only in this race | |
| Vesatolimod | Phase 2 | Small molecule | Toll-like receptor 7 (TLR7) (agonist) | Weak signal | Featured results are safety only in this race | |
| VH4004280 (VH-280) | Phase 2 | Small molecule | HIV capsid | Partial signal | NCT06039579: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574) | |
| VH4524184 | Phase 2 | Small molecule | HIV integrase | Partial signal | NCT06214052: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37) | |
| JL18008 | Phase 1/2 | Protein / enzyme therapeutic | IL-7 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| LP-98 | Phase 1/2 | Peptide | HIV gp41 | Partial signal | No reviewed efficacy summary in this indication | |
| AGT103-T | Phase 1 | Gene therapy / editing | HIV proviral reservoir / autologous T cells | Weak signal | Featured results are safety only in this race | |
| Ainuovirine | Phase 1 | Small molecule | HIV reverse transcriptase | Weak signal | Featured results are safety only in this race | |
| AV000103A (ICVAX) | Phase 1 | Vaccine | HIV antigens | Weak signal | Featured results are safety only in this race | |
| BNT168 | Phase 1 | Vaccine | HIV antigens | not yet graded | No reviewed efficacy summary in this indication | |
| BNT351 | Phase 1 | Monoclonal antibody | HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| CPT31 | Phase 1 | Peptide | HIV gp41 | Weak signal | Featured results are safety only in this race | |
| MGD014 | Phase 1 | Multispecific antibody | HIV envelope gp120 x CD3 | Weak signal | Featured results are safety only in this race | |
| MGD020 | Phase 1 | Multispecific antibody | HIV envelope gp41 x CD3 | Weak signal | Featured results are safety only in this race | |
| MK-4646 | Phase 1 | Small molecule | — | Weak signal | No reviewed efficacy summary in this indication | |
| UVAX-1107 | Phase 1 | Vaccine | HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| VH4770359 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Islatravir / Ulonivirine | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| YASO GEL | —(overall) | Small molecule | HIV gp120 | not yet graded | No reviewed efficacy summary in this indication | |
| Fosamprenavir (Lexiva / Telzir) | Discontinued | Small molecule | HIV protease | Partial signal | NCT00450580: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks (Week 48): FPV/RTV 1400/100 mg Once Daily (QD) + ABC/3TC FDC 600/300 mg Q — HIV-1 RNA <400 copies/mL: 81%; HIV-1 RNA >=400 copies/mL: 19% | FPV/RTV 700/100 mg BID + ABC/3TC FDC 600/300 mg QD — HIV-1 RNA <400 copies/mL: 82%; HIV-1 RNA >=400 copies/mL: 18% NCT00363142: Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24 (Week 24): FPV/r100 92.1% | FPV/r200 94.2% | |
| VH4527079 | Discontinued | Multispecific antibody | HIV entry | not yet graded | No reviewed efficacy summary in this indication | |
| Zegruvirimat | Discontinued | Small molecule | HIV-1 Gag maturation (CA-SP1 cleavage) | Partial signal | NCT06061081: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA). (From Day 1 to Day 8): VH3739937 Low Dose Group -116909.43 copies/milliliter (c/mL) (Standard Deviation 187489.611) | VH3739937 Medium Dose Group -130461.67 copies/milliliter (c/mL) (Standard Deviation 106486.489) | VH3739937 High Dose Group -126026.67 copies/milliliter (c/mL) (Standard Deviation 190725.475) vs Placebo Once Daily (QD) -428000 copies/milliliter (c/mL) | Placebo Single Dose (SD) -14200 copies/milliliter (c/mL) |
Compare side by side
7 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Descovy (Tenofovir alafenamide/emtricitabine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.